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Abstract 
Introduction 
Atypical antipsychotics are 
increasingly prescribed for women 
suffering affective and non-affective 
psychoses during the antenatal and 
postnatal period. The level of evidence 
for psychopharmacological treatment 
during pregnancy with these agents is 
generally poor, especially on 
maternal, foetal and infant outcomes. 
The aim is to summarize the current 
evidence on the use of atypical 
antipsychotics during pregnancy, and 
to evaluate the known maternal, foetal 
and neonatal outcomes related to 
maternal treatment with atypical 
antipsychotic during the antenatal 
period. 
Materials and methods 
A comprehensive literature search 
was undertaken by using various 
electronic databases to identify 
published studies reporting on safety 
of atypical antipsychotics in human 
pregnancy up to March 2014. We 
inspected all references of all 
identified studies and hand searched 
for key journals. The selected studies 
were reviewed, summarised, and 
synthesised. 
Results 
Atypical antipsychotics are known to 
be associated with maternal weight 
gain, which can increase risks of 
maternal gestational diabetes, 
metabolic syndrome, and foetal neural 
tube defects. Single cases of 
obstetrical complications and 
perinatal adverse reactions associated 
with exposure to atypical agents 
during pregnancy have also been 
reported. Conversely, there is no 
conclusive evidence of their structural 
teratogenicity. 
Conclusion 
The rapid development in 
pharmacotherapy has resulted in a 
growing number of women of 
childbearing age being treated with 
atypical antipsychotic drugs. The 
major challenge for healthcare 
professionals is to achieve an optimal 
balance between minimizing foetal 
and neonatal exposure whilst avoiding 
the potentially harmful consequences 
of maternal mental illnesses. Due to 
the limitation of the research and the 
potential public health implications, 
further evidence on maternal, 
obstetric and infant outcomes of 
mother treated with atypical 
antipsychotics is urgently needed. 
  
Introduction 
Over the past ten years the 
importance of maternal mental health 
has become clear. In the sixth report 
of the UK Confidential Enquiry into 
Maternal and Child Health (CEMACH), 
mental illness was the leading cause of 
maternal death1. The numbers of 
maternal deaths from indirect 
psychiatric causes in the UK continues 
to outnumber direct deaths and has 
been demonstrated in the past four 
CEMACH reports where the mortality 
rate for mothers’ deaths with either 
pre-existing or new major mental 
illnesses precipitated by pregnancy 
remains largely unchanged2. Typically 
mothers with a mental illness who die 
in the postpartum period are suffering 
from a severe psychotic illness. 
   The global prevalence of non-
affective psychotic illnesses, such as 
Schizophrenia, is relatively rare. 
Epidemiological data indicates that 
their lifetime prevalence and 
incidence are 0.30−0.66% and 10.2–
22.0 per 100.000 person-years, 
respectively3. Literature evidence 
shows higher prevalence and incidence 
rates in general population4,5 for 
affective psychosis, such as Bipolar 
Affective Disorder which has an 
estimated lifetime prevalence of 
approximately about 2–4%6. The 
prevalence of Puerperal Psychosis (a 
psychotic episode precipitated by 
childbirth) is approximately 1-2 case 
per 1000 deliveries in the general 
population7. BPAD and, to a lesser 
extent, Schizophrenia have elevated 
prevalence in Puerperal Psychosis8. 
Women with a history of Puerperal 
Psychosis are at extremely high risk of 
relapse in new pregnancies and 
postpartum is the time of major risk for 
exacerbation of a psychotic episode9,10.  
   The risk–benefit weighting of 
treatment versus no treatment in the 
puerperium for women who have had a 
prior episode of Puerperal Psychosis 
falls down very convincingly on the side 
of active prophylactic treatment8,11.  
   However, there is no conclusive 
consensus regarding the most suitable 
time to reintroduce prophylaxis. Some 
authors suggest starting prophylaxis 
during the second or third trimester of 
pregnancy12 when the teratogenesis 
risk is thought to be lower, while other 
authors suggest deferring prophylactic 
treatment immediately after delivery11.  
   Other particularly vulnerable women, 
on the other hand, may require 
medication throughout pregnancy8, and 
antipsychotic drugs remain an 
important treatment option during 
pregnancy to properly manage a 
psychotic illness13. In evaluating any 
negative effects of taking medication 
during pregnancy concerns include: 
whether there is an increased risk of 
miscarriage; the risks of major 
malformations in the baby; any 
obstetric and neonatal complication; 
safety during breastfeeding and the 
occurrence of long-term problems in 
the offspring. Any of these concerns 
must be weighed against the risks of 
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relapse of the mental illness. Thus, 
although foetal medication exposure 
is identified as a risk to pregnancy 
outcome, maternal mental illness and 
its risks to the foetus must also be 
clearly evaluated when considering 
treatment during pregnancy14,15,16. 
   In May 2008, the American Food and 
Drug Administration (FDA) proposed 
major revisions to prescription drug 
labelling during pregnancy and 
breastfeeding. The proposed 
regulations eliminate the current 
pregnancy categories of risk A, B, C, D, 
and X due to limitations in their ability 
to accurately and consistently convey 
risks and benefits, and the ultimate 
regulation is still in the writing and 
clearance process at present 17. 
   The atypical antipsychotics are now 
gradually replacing typical 
antipsychotics, as approved by the 
Medicines and Healthcare Products 
Regulatory Agency (MHRA) and the 
FDA, and are recommended as first-
line agents for non-affective psychotic 
disorders, such as Schizophrenia, as 
well as other disorders such as the 
treatment of acute mania and bipolar 
depression, and the maintenance 
treatment for bipolar disorder.  
   Women treated with these prolactin-
sparing agents, with the exception of 
risperidone, theoretically will have 
normal fertility rates (as the increased 
prolactin levels inhibited ovulation in 
typical antipsychotic use), thus being 
more likely to become pregnant than 
those receiving typical antipsychotics. 
Due to these potential changes in 
fertility rates in women using atypical 
antipsychotics, there is reason to 
believe that more women with 
psychotic disorders prescribed these 
medications will become pregnant in 
the future18. Consequently, data 
regarding the reproductive safety of 
these compounds bear tremendous 
public health implications19. 
   The aim of this critical review is to 
summarize the current evidence on 
the use of atypical antipsychotics 
during pregnancy, and to evaluate the 
known maternal, foetal and neonatal 
outcomes related to maternal 
treatment with atypical antipsychotic 
during the antenatal period. 
  
Materials and methods 
A comprehensive literature search 
was undertaken by using various 
electronic databases to identify 
published studies reporting on safety 
of atypical antipsychotics in human 
pregnancy up to March 2014. Five 
databases (no language restriction) 
have been used which include: 
Medline, Embase, Cochrane Library, 
PsychINFO and CINAHL. Initial search 
terms included antipsychotics 
(including specific searches for each 
currently used atypical antipsychotic), 
drug, atypical in combination with 
pregnancy, maternal, foetal and 
neonatal outcome, puerperium, and 
puerperal psychosis.  
   All papers available were accessed. 
We inspected all references of all 
identified studies and hand searched 
for key journals. Due to the paucity of 
well-designed prospective studies, a 
formal appraisal of evidence was not 
conducted. Where case reports, 
manufacturers’ data and other smaller 
studies have been included, the 
limitation of this evidence has been 
noted. 
  
Results 
Current use of atypical 
antipsychotics during pregnancy 
In the UK the proportion of time 
patients spent on typical 
antipsychotics for Bipolar Affective 
Disorder in 1995 was 14.2%. By 2009 
this had reduced to 6.9%. In contrast, 
the proportion of time spent on 
atypical antipsychotics had increased 
from zero to 35.0%20. The annual 
proportion of time patients spent in 
atypical antipsychotic treatment for 
Schizophrenia increased from 16.6% 
to 51.2% between 1998-2007, 
whereas time spent in typical 
antipsychotic treatment reduced from 
37.1% to 15.0% during the same 
period21.  
   According to literature evidence 
approximately 0.053% of the women 
took an atypical antipsychotic at some 
point during the antenatal period22, 
while other authors recently showed a 
2.5-fold increase in atypical 
antipsychotic use during pregnancy 
up until 0.82 %23. 
 Pregnancy and obstetric outcomes 
Most existing studies of pregnancy/ 
obstetric outcome in association with 
maternal psychotropic treatment 
during pregnancy have relied on 
maternal self-reports, assuming 100% 
maternal compliance. To date to our 
knowledge, there have been no blinded 
or randomized studies examining birth 
outcomes in women taking atypical 
antipsychotics. There are two 
prospective study24,25, one descriptive 
cohort study26 and the remainder of the 
data come from case reports and 
manufacturers’ data collections18. Both 
case reports and manufacturers’ data 
may show a reporting bias that could 
over represent the rate of adverse 
outcomes. 
   Atypical antipsychotics are known to 
be associated with weight gain24, which 
can increase risks to both mother and 
baby, such as the risk of maternal 
obesity, gestational diabetes, metabolic 
syndrome and the baby being at higher 
risk for neural tube defects27. 
   Weight gain and related metabolic 
syndrome have been reported in 
association with olanzapine, as well as 
other atypical antipsychotics including 
clozapine and quetiapine28. Women 
exposed to these agents have generally 
higher BMI compared to not exposed 
women25. There are also reports on the 
association between atypical anti-
psychotics and increased risk of 
gestational diabetes29,30. Similar risks 
occur for the more obesogenic and 
diabetogenic antipsychotics clozapine 
and olanzapine as for other 
antipsychotics, which suggest similar 
effects30. 
   In addition, women with excessive 
weight gain are more likely to have pre-
existing hypertension or to develop this 
condition during pregnancy26,31, while 
other authors found an increased risk 
of hypothyroidism in women exposed 
to atypical agents26. 
   Literature research has shown that 
gestational diabetes can leads to higher 
risk of low for gestational age (LGA) 
babies30.  
   Newham et al. found that infant 
exposed to atypical antipsychotics had 
a significantly higher incidence of being 
LGA32, while other authors found that 
atypical antipsychotics exposure during 
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pregnancy is not significantly 
associated with LGA babies, with the 
exception of olanzapine and/or 
clozapine exposure being related to 
macrocephaly30. A small, Australian 
database has shown two cases of high 
neural tube defects resulting in early 
second trimester miscarriages in 
women receiving aripiprazole in 
pregnancy33, while other authors did 
not detect a significantly increased 
risk of miscarriage (<20 weeks)25,26 
and foetal death (≥20 weeks)26 after 
exposure to antipsychotics which is in 
line with the findings of other 
investigators25,34. Single cases of poor 
pregnancy outcome, and perinatal 
adverse reactions associated with 
exposure to clozapine during 
pregnancy have been reported, 
though they have been shown only in 
case reports and/or small case series.  
   A report from the Lilly Worldwide 
Pharmacovigilance Safety Database 
identified some cases of complicated 
pregnancy outcome in women under 
olanzapine treatment. In contrast, 
there are a number of other reports 
describing healthy outcomes in babies 
exposed to olanzapine throughout 
pregnancy18.  
   Only sporadic clinical observations 
have described complicated 
pregnancy outcomes following in 
utero exposure to risperidone that 
were consistent with rates in the 
general population34. Overall, the 
obstetrical complications found in 
literature include preterm deliveries 
(26), increased rate of instrumental 
deliveries26, low birth weight babies24, 
greater mean birth weight25,32, 
increased neonatal intensive care unit 
admissions19,26, and poor neonatal 
adaptation signs (central nervous 
system, respiratory and 
gastrointestinal problems)26,35.  
   Several studies have described an 
increased risk of preterm birth in 
women treated with atypical agents, 
but it is not clear if it is a specific effect 
of treatment or a consequence of the 
mental illness itself. 
 
Foetal, neonatal and child 
outcomes 
There is no conclusive evidence of the 
structural teratogenicity of atypical 
antipsychotics. Manufacturers’ data 
collections report that prevalence of 
major malformations does not differ 
from that detected in general 
population18. Most prospective and 
retrospective studies have not been 
found related to increased risk of 
major malformations in infant 
exposed to these agents7,18,24, 
25,29,34,36,37, while a recent prospective 
observational cohort study from 
Habermann et al.25 showed an 
increased rate of cardiovascular 
defects in offspring of mothers treated 
with atypical antipsychotics during 
pregnancy. Newport et al. found 
placental passage ratio for quetiapine 
and olanzapine being respectively the 
lowest (24.1%) and the highest 
(72.1%) compared to other atypical 
agents19. Knowledge concerning 
placental passage of clozapine is 
limited, with only one case report 
documenting foetal accumulation30. 
   Sporadic cases of olanzapine-
associated neonatal adverse reactions, 
self-remitted neuro-developmental 
impairment are now being recorded. 
An increased risk of hypoglycaemia 
has been seen in newborns of mothers 
treated with atypical agents24,32.  
   Several authors report cases of 
neonatal convulsion and floppy baby 
syndrome in women taking clozapine 
during pregnancy29, while clozapine 
overdose during pregnancy may lead 
to fatal poisoning of the newborn18. 
Other authors found speech problems 
in children of mother exposed to 
clozapine38. Self-limiting extra-
pyramidal or possible withdrawal 
symptoms have also been described in 
infant exposed to risperidone in the 
third trimester34.  
Other atypical antipsychotic drugs, 
asenapine, paliperidone, ziprasidone 
and sertindole have not been used 
adequately to meaningfully discuss 
risks of treatment during 
pregnancy18,29,31. 
  
Discussion 
The rapid development in 
pharmacotherapy has resulted in a 
growing number of women of 
childbearing age being treated with 
atypical antipsychotic medications39.  
   While there have been many 
literature reviews related to this topic, 
for the clinician there remains 
insufficient evidence relating to best 
practice in using antipsychotic 
medication during pregnancy. 
Moreover, current clinical practice 
varies. This variation is attributable to 
clinician’s awareness of the lack of 
substantial evidence and their 
uncertainty that treatment will work 
and, at the same time, will cause no 
harm to either mother or baby.  
   While long-term studies gathering 
controlled prospective data from large 
numbers of women are required, due to 
ethical issues no studies of medication 
during pregnancy meet the gold 
standard of randomized, placebo-
controlled, double-blind, crossover 
trials. Despite the limitations of the 
research, it is still necessary to make 
recommendations based on the 
accumulated information of the best 
available studies on the safety of 
antipsychotic medication during 
pregnancy or breastfeeding.  
   Obstetricians, psychiatrists, and 
general practitioners need strong 
evidence on which to base prescribing 
of atypical antipsychotic drugs for 
pregnant and breastfeeding women, 
and women must be provided with 
reliable information to support them in 
decisions about medication during 
pregnancy and after childbirth. 
   The use of atypical antipsychotics 
during pregnancy is described as 
appropriate in clinical situations where 
the risk of prenatal exposure is 
outweighed by the risk of relapse if the 
drug were to be discontinued39. Current 
literature evidence provide no 
conclusive information about the best 
treatment option with antipsychotics 
(typical or atypical) during pregnancy. 
Although atypical antipsychotics are 
thought to be safer than typical 
antipsychotics18, they still have side 
effects40, that all confer significant risks 
for pregnancy. A recent systematic 
review from Gentile et al.18 suggest 
using typical antipsychotics, especially 
chlorpromazine, instead of atypical 
agents for the management of psychotic 
symptoms in pregnant drug-naïve 
women, while when an unplanned 
pregnancy occurs during antipsychotic 
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treatment with either typical or 
atypical agents, the choice to continue 
the previous therapy (if known as 
effective) should be preferred.  
   Clinical outcome studies following 
antenatal atypical antipsychotic 
administration are limited to analyses 
using small sample sizes of placental 
passage rates, neonatal outcomes and 
the risk for delivery complications and 
congenital malformations.  
   Thus, further investigation on the 
outcomes of women treated with 
atypical antipsychotic medications in 
pregnancy for any psychotic disorder 
and the consequences of this 
treatment on maternal, obstetric and 
infant outcomes urgently need to be 
characterised to inform the global 
evidence base for the management of 
these women in pregnancy. 
  
Conclusion 
The management of expectant 
mothers with psychotic illness poses a 
challenge for patients, their families, 
and obstetricians. The major goal is to 
achieve an optimal balance between 
minimizing foetal and neonatal 
exposure to drugs whilst avoiding the 
potentially serious consequences of a 
mother developing psychosis. 
   Literature evidence have highlighted 
the importance to start or continue 
antipsychotic therapy in vulnerable 
women due to the risk of relapse of 
their mental illness, which in some 
case represents a medical and 
obstetrical emergency. 
   The majority of studies on the 
reproductive safety of antipsychotic 
drugs are based on a single-dimension 
experimental design, which could 
underestimate all the possible factors 
related to the increased risk of poor 
pregnancy, obstetrical and neonatal 
outcomes independent of the 
medication itself. At present, the best 
available data on antipsychotic 
treatment during pregnancy come 
from non-randomized, prospective/ 
observational studies, case reports or 
manufacturers’ data. Further evidence 
is required from large pragmatic 
studies that reflect routine clinical 
practice, examine a broad range of 
outcomes and accurately quantify 
risks and benefits to both mothers and 
their offspring, so that comparison 
between different treatment options 
can be made. 
 
References 
1. Confidential Enquiry into Maternal 
and Child Health. Why Mothers Die 
2000–2002: The Sixth Report of the 
Confidential Enquiries into Maternal 
Death in the United Kingdom. London: 
RCOG Press, 2004. 
2. CMACE. Saving mothers’ lives: 
reviewing maternal deaths to make 
motherhood safer: 2006e2008. The 
Eighth Report of the Confidential 
Enquiries into Maternal Deaths in the 
United Kingdom. Br J Obstet Gynaecol. 
2011; 118(suppl 1): 1e203. 
3. McGrath J, Saha S, Chant D, Welham 
J. Schizophrenia: a concise overview of 
incidence, prevalence, and mortality. 
Epidemiol Rev. 2008; 30: 67–76. 
4. Kirkbride JB, Errazuriz A, Croudace 
TJ, Morgan C, Jackson D, et al. 
Incidence of Schizophrenia and Other 
Psychoses in England, 1950–2009: A 
Systematic Review and Meta-
Analyses. PLoS ONE. 2012; 7(3): 
e31660. 
5. Regeer EJ, ten Have M, Rosso 
ML, Hakkaart-van Roijen L, Vollebergh 
W, Nolen WA. Prevalence of bipolar 
disorder in the general population: a 
Reappraisal Study of the Netherlands 
Mental Health Survey and Incidence 
Study. Acta Psychiatr Scand. 
2004;110(5):374-82. 
6. Ketter TA. Diagnostic features, 
prevalence,and impact of bipolar 
disorder. J. Clin. Psychiatry. 2010; 
71(6), e14.  
7. McCauley-Elsom K, Kulkarni J. 
Managing psychosis in pregnancy. 
Australian and New Zealand Journal of 
Psychiatry. 2007; 41 (3): 289-292. 
8. Chaudron LH, Pies RW. The 
relationship between postpartum 
psychosis and bipolar disorder: a 
review. Journal of Clinical Psychiatry. 
2003; 64: 1284-1292. 
9. Maina G, Rosso G, Aguglia A, Bogetto 
F. Recurrence rates of bipolar 
disorder during the postpartum 
period: a study on 276 medication-
free Italian women. Arch Womens 
Ment Health. 2014 Jan 22. [Epub ahead 
of print] 
10. Robertson E, Jones I, Haque S et al. 
Risk of puerperal and non-puerperal 
recurrence of illness following bipolar 
affective puerperal (postpartum) 
psychosis. British Journal of Psychiatry. 
2005; 186: 258-259. 
11. Bergink V, Bouvy PF, Vervoort JS, 
Koorengevel KM, Steegers EA, Kushner 
SA. 
Prevention of postpartum psychosis an
d mania in women at high risk. Am J 
Psychiatry. 2012 Jun;169(6):609-15. 
12. Grof P, Robbins W, Alda M et al. 
Protective effect of pregnancy in 
women with lithium-responsive bipolar 
disorder. J Affect Disord. 2000; 61: 31-
39. 
13. Oyebode F, Rastogi A, Berrisford G, 
Coccia F. Psychotropics in pregnancy: 
Safety and other considerations. 
Pharmacology and Therapeutics. 2012; 
135: 71-77. 
14. Yaeger D, Smith HG, Altshuler LL. 
Atypical Antipsychotics in the 
Treatment of Schizophrenia During 
Pregnancy and the Postpartum. Am J 
Psychiatry. 2006; 163:12. 
15. Maina G, Saracco P, Giolito 
MR, Danelon D, Bogetto F, Todros T. 
Impact of maternal psychological 
ditress on fetal weight, prematurity and 
intrauterine growth retardation. J Affect 
Disord. 2008 Dec;111(2-3):214-20. 
16. Paschetta E, Berrisford G, Coccia 
F, Whitmore J, Wood AG, Pretlove 
S, Ismail KM. Perinatal psychiatric 
disorders: an overview. Am J Obstet 
Gynecol. 2013; pii: S0002-
9378(13)01047-8. 
17. U.S. Food and Drug Administration. 
Pregnancy and Lactation labelling. 
Available 
from:http:www.fda.gov/drugs/develop
mentapprovalprocess/developmentres
ources/labeling/ucm093307.htm. 
Accessed March 31, 2014. 
18. Gentile S. Antipsychotic Therapy 
During Early and Late Pregnancy. A 
Systematic Review Schizophrenia 
Bulletin. 2010; 36 (3): 518–544. 
19. Newport DJ, Calamaras MR, DeVane 
CL., Donovan, J, Beach AJ, Winn S, 
Knight BT, Gibson BB, Viguera AC, 
Owens MJ, Nemeroff CB, Stowe ZN. 
Atypical antipsychotic administration 
during late pregnancy: placental 
Page 5 of 5 
Licensee OAPL (UK) 2014. Creative Commons Attribution License (CC-BY) 
FOR CITATION PURPOSES: Paschetta E, Rosso G, Maina G. Atypical antipsychotics, maternal and child outcomes: A 
critical review. OA Women's Health 2014 Jan 18;2(1):2.  
 
Critical review 
 
 
C
o
m
p
et
in
g
 in
te
re
st
s:
 N
o
n
e 
d
ec
la
re
d
.  
C
o
n
fl
ic
t 
o
f 
in
te
re
st
s:
  N
o
n
e 
d
ec
la
re
d
.  
A
ll 
a
u
th
o
rs
 c
o
n
tr
ib
u
te
d
 t
o
 c
o
n
ce
p
ti
o
n
 a
n
d
 d
es
ig
n
, m
a
n
u
sc
ri
p
t 
p
re
p
a
ra
ti
o
n
, r
ea
d
 a
n
d
 a
p
p
ro
ve
d
 t
h
e 
fi
n
a
l m
a
n
u
sc
ri
p
t.
  
A
ll 
a
u
th
o
rs
 a
b
id
e 
b
y 
th
e 
A
ss
o
ci
a
ti
o
n
 f
o
r 
M
ed
ic
a
l E
th
ic
s 
(A
M
E)
 e
th
ic
a
l r
u
le
s 
o
f 
d
is
cl
o
su
re
. 
 
passage and obstetrical outcome. Am J 
Psychiatry. 2007; 164: 1214–1220. 
20. Hayes J, Prah P, Nazareth I, King M, 
Walters K, Petersen I, Osborn D. 
Prescribing trends in bipolar disorder: 
cohort study in the United Kingdom 
THIN primary care database 1995-
2009. PLoS One. 2011; 6(12):e28725. 
21. Prah P, Petersen I, Nazareth I, 
Walters K, Osborn D. National changes 
in oral antipsychotic treatment for 
people with schizophrenia in primary 
care between 1998 and 2007 in the 
United Kingdom. Pharmacoepidemiol 
Drug Saf. 2012; 21(2):161-9. 
22. Wichman CL. Atypical 
antipsychotic use in pregnancy: A 
retrospective review. Archives of 
Women's Mental Health. 2009; 12 (1): 
53-57. 
23. Toh S, Li Q, Cheetham TC, Cooper 
WO, Davis RL, Dublin S, Hammad 
TA, Li DK et al. Prevalence and trends 
in the use of 
antipsychotic medications during 
pregnancy in the U.S., 2001-2007: a 
population-based study of 585,615 
deliveries. Arch Womens Ment Health. 
2013;16(2):149-57. 
24. McKenna K, Koren G, Tetelbaum 
M, Wilton L, Shakir S, Diav-Citrin 
O, Levinson A, Zipursky RB, Einarson 
A. Pregnancy outcomes of women 
using atypical antipsychotic drugs: a 
prospective comparative study. J Clin 
Psychiatry. 2005;66(4):444-9; quiz 
546. 
25. Habermann F, Fritzsche 
J, Fuhlbrück F, Wacker E, Allignol 
A, Weber-Schoendorfer C, Meister 
R, Schaefer C. Atypical antipsychotic 
drugs and pregnancy outcome: a 
prospective, cohort study. J Clin 
Psychopharmacol. 2013;33(4):453-
62. 
26. Sadowski A, Todorow M, Yazdani 
Brojeni P, Koren G, Nulman I. 
Pregnancy outcomes following 
maternal exposure to second-
generation antipsychotics given with 
other psychotropic drugs: a cohort 
study. BMJ Open. 2013;3(7).  
27.Koren G, Cohn T, Chitayat D, Kapur 
B, Remington G, Reid DM, Zipursky 
RB. Use of atypical anti-
psychotics  during pregnancy and the 
risk of neural tube defects in infants. 
Am J Psychiatry. 2002;159 (1):136-7.  
28. Newcomer JW. Metabolic 
considerations in the use of 
antipsychotic medications: a review of 
recent evidence. J Clin 
Psychiatry. 2007;68 Suppl 1:20-7. 
29. McCauley-Elsom K, Gurvich 
C, Elsom SJ, Kulkarni J. Antipsychotics 
in pregnancy. J Psychiatr Ment Health 
Nurs. 2010;17(2):97-104. 
30. Bodén R, Lundgren M, Brandt 
L, Reutfors J, Kieler H. Antipsychotics 
during pregnancy: relation to fetal and 
maternal metabolic effects. Arch Gen 
Psychiatry. 2012;69(7):715-21. 
31. Einarson A, Boskovic R. Use 
and  safety of antipsychotic drugs 
during pregnancy. J Psychiatr Pract. 
2009;15(3):183-92. 
32. Newham JJ, Thomas SH, 
MacRitchie K, McElhatton PR, 
McAllister-Williams RH. Birth weight 
of infants after maternal exposure to 
typical and atypical antipsychotics: 
prospective comparison study. BJP. 
2008; 192:333-337. 
33. Kulkarni J, McCauley-Elsom 
K, Marston N, Gilbert H, Gurvich C, de 
Castella A, Fitzgerald P. Preliminary 
findings from the National Register of 
Antipsychotic Medication in 
Pregnancy. Aust N Z J Psychiatry. 2008 
;42(1):38-44. 
34. Coppola D, Russo LJ, Kwarta RF Jr, 
Varughese R, Schmider J. Evaluating 
the postmarketing experience of 
risperidone use during pregnancy: 
pregnancy and neonatal outcomes. 
Drug Safety. 2007; 30(3):247-64. 
35. Mendhekar DN, Sunder KR, 
Andrade C. Aripiprazole use in a 
pregnant schizoaffective woman. 
Bipolar Disorders. 2006; 8: 299–300. 
36. Goldstein DJ, Corbin LA, Fung MC. 
Olanzapine-exposed pregnancies and 
lactation: early experience. J Clin 
Psychopharmacol. 2000; 20:399-403. 
37. Reis M, Kallen B. Maternal Use of 
Antipsychotics in Early Pregnancy and 
Delivery Outcome. Journal of Clinical 
Psychopharmacology. 2008; 28 (3): 
279-288. 
38. Mendhekar DN. Possible delayed 
speech acquisition with clozapine 
therapy during pregnancy and 
lactation. Journal of Neuropsychiatry 
Clinical Neuroscience. 2007;19: 196– 
197. 
39.Trixler M, Gati A, Fekete S, Tenyi T. 
Use of antipsychotics in the 
management of schizophrenia during 
pregnancy. Drugs. 2005; 65(9): 1193-
206.  
40. Weiden PJ. EPS profiles: the atypical 
antipsychotics are not all the same. J 
Psychiatr Pract. 2007; 13 (1): 13–24.  
  
 
 
